Study Of Role Of Lipoxin – A4 In Psoriasis

The aim of this work was to evaluate the level of lipoxin – A4 (LXA4) in patients with psoriasis and its correlation with clinical parameters. This study included 25 psoriatic patients who were recruited from the outpatient clinics of dermatology department, Faculty of Medicine, Beni-Suef University. In addition, 25 age and sex-matched volunteers were included as control group. Four mm punch skin biopsy will be taken from the tissue and will be kept in lysis solution for the stability of the studied parameters and will be kept frozen at -80°C till detection of LXA4 in tissue by real time-PCR. Peripheral blood samples for serum LXA4 are taken. Blood samples will be centrifuged and serum will be stored at 80°C and used for ELISA. The LPXA levels in the case ranged from 1.01 -7.8 ng/mL with a mean of 2.94 ±1.7 ng/mL. In addition, the LXA4 levels in the control ranged from 4.5 – 14.7 ng/mL with a mean of 9.45 ±2.26 ng/mL. The level of LXA4 is significantly downregulated in patients with psoriasis, compared to healthy volunteers. Moreover, the affection of LXA4 appears to be correlated with the severity of the diseases. LXA4 and its analogue may be potential therapeutic candidates for psoriasis.